CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%

Stock News

03/19

CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236 billion, representing a decrease of 3.08% year-on-year. However, net profit attributable to shareholders of the listed company reached RMB 1.105 billion, marking a year-on-year increase of 15.63%. Basic earnings per share were RMB 0.74. The board proposed a cash dividend distribution of RMB 1.00 per 10 shares (tax inclusive).

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1162742200"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1162742200\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1162742200?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 18:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1162742200","market":"us","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%","media":"Stock News","content":"<p>CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236 billion, representing a decrease of 3.08% year-on-year. However, net profit attributable to shareholders of the listed company reached RMB 1.105 billion, marking a year-on-year increase of 15.63%. Basic earnings per share were RMB 0.74. The board proposed a cash dividend distribution of RMB 1.00 per 10 shares (tax inclusive).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Reports Tasly Pharmaceutical's 2025 Net Profit Attributable to Shareholders at RMB 1.105 Billion, Up 15.63%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-19 18:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236 billion, representing a decrease of 3.08% year-on-year. However, net profit attributable to shareholders of the listed company reached RMB 1.105 billion, marking a year-on-year increase of 15.63%. Basic earnings per share were RMB 0.74. The board proposed a cash dividend distribution of RMB 1.00 per 10 shares (tax inclusive).</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"國家隊","start_time":0,"source_url":"","article_id":"1162742200","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1162742200","pubTimestamp":1773916102,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600535":"天士力","BK0028":"国家队","BK1574":"生物医药B类股","03320":"华润医药","BK0239":"医药制造","BK0183":"MSCI概念","BK1515":"抗疫概念","BK1191":"制药","BK0188":"融资融券","BK1161":"生物科技","BK1570":"华润系","BK0012":"证金概念","BK0196":"行业龙头","09939":"开拓药业-B"},"translate_title":"CHINARES PHARMA(03320)公布天士力制药2025年归属股东净利润11.05亿元增15.63%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600535":1,"09939":1,"03320":1},"content_text":"CHINARES PHARMA (03320) announced the annual results for Tasly Pharmaceutical Group Co., Ltd. for the period ending December 31, 2025. The company reported total operating revenue of RMB 8.236 billion, representing a decrease of 3.08% year-on-year. However, net profit attributable to shareholders of the listed company reached RMB 1.105 billion, marking a year-on-year increase of 15.63%. Basic earnings per share were RMB 0.74. The board proposed a cash dividend distribution of RMB 1.00 per 10 shares (tax inclusive).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}